期刊文献+

代谢综合征患者血清白介素10与胰岛素抵抗的关系 被引量:9

Relationship between serum interleukin-10 and insulin resistance in metabolic syndrome
下载PDF
导出
摘要 目的探讨代谢综合征(MS)患者胰岛素抵抗(IR)与血清白介素10(IL-10)水平的关系。方法 MS患者及年龄相匹配的正常对照组各18例。以高胰岛素-正常血糖钳夹技术检测葡萄糖代谢率(M值),评价IR程度:采用酶联免疫吸附法检测血清IL-10水平,用Pearson相关分析法分析血清IL-10水平与M值的相关性。结果 MS组M值显著低于对照组[(5.76±1.81)mg/kg·min vs (8.39±1.25)mg/kg·mim,P<0.05];MS组血清IL-10水平显著低于对照组[1.3(0.8/3.1) pg/ml vs 2.4(1.1/4.5)pg/ml,P<0.05];Pearson相关分析法显示血清IL-10水平与M值正相关(P<0.05)。结论 MS患者血清IL-10水平降低,可能与IR的发生有关。 Objective To investigate the relationship between serum interleukin-10 (IL-10) level and insulin resistance (IR) in patients with metabolic syndrome (MS). Methods Eighteen MS subjects and 18 age-matched normal subjects were enrolled. IR was evaluated by hyperinsulinemic-euglycemic clamp technique and serum IL-10 level measured by ELISA. Pearson's correlation analysis was used to investigate the relationship between serum IL-10 level and IR. Results Serum IL-10 levels were significantly higher in patients with MS than in the controls [1.3 (0.8/3.1) pg/ml vs 2.4 (1.1/4.5) pg/ml, P〈0.05], and glucose metabolic rate (M value) derived from hyperinsulinemic-euglycemic clamp technique was lower in MS subj ects than in controls [(5.76±1.81) mg/kg.min vs (8.39±1.25) mg/kg.min],P〈0.05]. Serum IL-10 levels showed a positive correlation with M value (P〈0.05). Conclusion Patients with MS have greater IR and lower serum IL-10 levels than normal subjects, and lowered IL-10 levels might be involved in the pathogenesis of IR in MS.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2006年第4期428-430,共3页 Journal of Southern Medical University
基金 教育部博士点基金(002000001) 卫生部基金(000099009)
关键词 代谢综合症 白介素-10 胰岛素抵抗 葡萄糖钳夹技术 metabolic syndrome intedeukin-10 insulin resistance hyperinsulinemic-euglycemic clamp
  • 相关文献

参考文献12

  • 1Ziccardi P,Nappo F,Giugliano G,et al.Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year[J].Circulation,2002,105(7):804-9.
  • 2Thorand B,Kolb H,Baumert J,et al.Elevated levels of interleukin-18 predict the development of type 2 diabetes:results from the Monica/Kora augsburg study,1984-2002 [J].Diabetes,2005,54(10):2932-8.
  • 3Bluher M,Fasshauer M,Tonjes A,et al.Association ofinterleukin-6,C-reactive protein,interleukin-10 and adiponectin plasma concentrations with measures of obesity,insulin sensitivity and glucose metabolism [J].Exp Clin Endocrinol Diabetes,2005,113(9):534-7.
  • 4宋秀霞 ,纪立农 .国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志(1006-6187),2005,13(3):178-180. 被引量:611
  • 5Defronzo RA,Tobin JD,Andres R.Glucose clamp technique:a method for quantifying insulin secretion and resistance [J].Am J Physiol,1979,237(3):E214-23.
  • 6贾伟平,陈蕾,项坤三,陆俊茜,包玉倩,薛凤仙,陆蔚.扩展高胰岛素-正葡萄糖钳夹技术的建立[J].中华内分泌代谢杂志,2001,17(5):268-271. 被引量:46
  • 7Fiorentino DF,Zlotnik A,Mosmann TR,et al.IL-10 inhibits cytokine production by activated macrophages [J].J Immunol,1991,147(11):3815-22.
  • 8Esposito K,Pontillo A,Giugliano F,et al.Association of low interleukin-10 levels with the metabolic syndrome in obese women[J].J Clin Endocrinol Metab,2003,88(3):1055-8.
  • 9Manigrasso MR,Ferroni P,Santili F,et al.Association between circulating adiponectin and interleukin-10 levels in android obesity:effects of weight loss [J].J Clin Endocrinol Metab,2005,90(10):5876-9.
  • 10van Exel E,Gussekloo J,de Craen AJ,et al.Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes:the leiden 85-plus study[J].Diabetes,2002,51(4):1088-92.

二级参考文献23

  • 1Lee K U,Diabetologia,1988年,31卷,285页
  • 2Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med,2003,4(suppl 6):s11-s18.
  • 3Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol,1994,73:460-468.
  • 4Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med,2003,115(suppl 8A):24s-28s.
  • 5Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care,2003,26:1513-1517.
  • 6Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes,2001,109:s548-559.
  • 7Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001,285:1585-1591.
  • 8Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004,27:1182-1186.
  • 9Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003,26:3230-3236.
  • 10Tuomilehto J, Lindstrm J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM, 2001,344:1343-1350.

共引文献653

同被引文献95

引证文献9

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部